Filing Analysis
Lineage Cell Therapeutics, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the quarter ending June 30, 2026.
- A press release containing the financial results was issued on August 6, 2026, as Exhibit 99.1.
Lineage Cell Therapeutics has withdrawn its application for a CIRM Grant (CLIN2) following feedback from the California Institute for Regenerative Medicine. The company intends to resubmit a revised application in January 2026 and states this withdrawal does not impact current clinical development of OPC1.
🚩 Red Flags
- Withdrawal of anticipated non-dilutive funding (CIRM Grant) may impact cash runway if resubmission is delayed or unsuccessful.
📋 Key Facts
- Company withdrew its CLIN2 grant application from CIRM on November 28, 2025.
- Withdrawal followed comments received from CIRM on November 24, 2025.
- No specific content deficiencies were identified in the original application.
- The company plans to resubmit a revised application in the January 2026 grant cycle.
- Current development of OPC1 and the DOSED clinical study remain unaffected by this decision.
Lineage Cell Therapeutics achieved its first development milestone under its collaboration agreement with Roche/Genentech for the OpRegen cell therapy program. This achievement triggers a $5 million milestone payment to be received within 30 days.
📋 Key Facts
- Achievement of the first development milestone under the Roche Agreement on November 20, 2025.
- Milestone is related to manufacturing and clinical advancements for OpRegen (RG6501) in treating geographic atrophy (GA).
- A $5 million payment will be received by Lineage within 30 days.
- 24.1% of the milestone payment is allocated to the Israel Innovation Authority.
- 21.5% of the milestone payment is allocated to Hadasit Medical Research and Development Ltd.
Lineage Cell Therapeutics, Inc. completed a block transaction under its at-the-market (ATM) offering program, selling 12 million common shares to Janus Henderson Investors.
🚩 Red Flags
- Significant dilution: Issuance of 12 million new shares increases the total share count, diluting existing shareholders.
📋 Key Facts
- Sold 12,000,000 common shares on November 12, 2025.
- Transaction conducted via an at-the-market (ATM) offering program.
- Purchase price of $1.75 per share.
- Gross proceeds totaled $21 million before fees and expenses.
- Counterparty is Janus Henderson Investors.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on November 6, 2025.
📋 Key Facts
- The company issued a press release regarding financial results for the quarter ending September 30, 2025.
- Filing date: November 6, 2025.
- Results are furnished under Item 2.02 and are not being filed for purposes of Section 18 of the Exchange Act.
Lineage Cell Therapeutics entered into a multi-year research collaboration agreement with William Demant Invest 2 Aps (WDI) to advance the preclinical development of its ReSonance auditory neuronal cell transplant program. The partnership aims to prepare the program for potential human clinical trials.
🚩 Red Flags
- Joint ownership of 'Project Results' may dilute Lineage's control over specific advancements derived from this collaboration.
📋 Key Facts
- Agreement date: August 22, 2025
- Partner: William Demant Invest 2 Aps (WDI)
- Funding: WDI will fund up to $12 million in research collaboration costs
- Term: Approximately three years
- Focus: Preclinical development of ReSonance (ANPI) for hearing loss treatment
- IP Terms: Parties jointly own Project Results, excluding discoveries relating to Lineage's proprietary platform technology
- Exit Provision: Includes a mechanism for one party to purchase the other's interest in project IP if clinical agreements are not reached.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal notification that a press release containing these results was issued on August 12, 2025.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were issued via press release as Exhibit 99.1
Lineage Cell Therapeutics, Inc. reported the results of its Annual Meeting of Shareholders held on June 26, 2025. The meeting included the election of seven directors and the approval of an amendment to the company's 2021 Equity Incentive Plan.
🚩 Red Flags
- Significant opposition to the Equity Incentive Plan (EIP) amendment, with over 11.5 million votes cast against it.
📋 Key Facts
- Shareholders approved an amendment (EIP Amendment) to increase the number of common shares available under the 2021 Plan by 19,500,000 shares.
- Seven directors were elected to hold office until the 2026 annual meeting: Michael H. Mulroy, Dipti Amin, Deborah Andrews, Angus C. Russell, Neal C. Bradsher, Brian M. Culley, and Anula Jayasuriya.
- Shareholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2025.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The EIP Amendment received 88,575,737 votes in favor and 11,560,925 votes against.
Lineage Cell Therapeutics announced positive 36-month visual acuity data from its Phase 1/2a clinical study of OpRegen (RG6501) for geographic atrophy (GA). The data showed sustained improvement in best corrected visual acuity (BCVA) and retinal structure through the three-year mark.
🚩 Red Flags
- Forward-looking statements include risks regarding the Israeli regional conflict potentially impacting manufacturing processes in Jerusalem, Israel.
📋 Key Facts
- 36-month follow-up data presented at Clinical Trials at the Summit (CTS) 2025.
- Cohort 4 patients (less advanced GA) showed sustained BCVA improvement: +6.2 ETDRS letters at 36 months compared to +5.5 letters at 24 months.
- Subgroup with extensive OpRegen bleb coverage saw a mean BCVA change of +9.0 ETDRS letters at 36 months (n=5).
- OCT analysis showed sustained retinal structural improvements in the ELM and RPEDC layers through month 36.
- The therapy is being developed under an exclusive worldwide collaboration with Roche and Genentech.
Lineage Cell Therapeutics, Inc. notified the company that its independent auditor, Moss Adams LLP, has merged with Baker Tilly US, LLP. Consequently, Moss Adams has resigned and Baker Tilly has been appointed as the successor auditor for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change: While driven by a merger rather than a dispute, auditor changes in micro-cap companies can sometimes lead to delays in financial reporting during the transition.
📋 Key Facts
- Moss Adams LLP merged with Baker Tilly US, LLP effective June 3, 2025.
- Baker Tilly is the successor independent registered public accounting firm.
- The appointment covers the fiscal year ending December 31, 2025.
- No disagreements regarding accounting principles or auditing procedures were reported between the company and Moss Adams.
- Moss Adams' audit report for the year ended Dec 31, 2024, was unqualified (no adverse opinion/disclaimer).
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2025. The filing serves as a formal notice that earnings data has been released via press release.
📋 Key Facts
- Report date: May 13, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the quarterly press release.
Lineage Cell Therapeutics announced the successful completion of a production run for two product candidates using a customized, two-tiered cGMP cell banking system. The company emphasized that this process is designed to enable scalable and cost-effective manufacturing from a single pluripotent cell line.
🚩 Red Flags
- Significant manufacturing complexity: The company notes that establishing lines from stem cells that proliferate without differentiating or developing mutations is challenging and resource-intensive.
- Scalability uncertainty: Management explicitly states there is no assurance they can consistently produce cGMP lots at a commercially viable scale in the future.
📋 Key Facts
- Completed production run for two different product candidates.
- Utilized a customized, two-tiered current Good Manufacturing Practice (cGMP) cell banking system.
- Process uses a genetically-stable master cell bank derived from a single pluripotent cell line to create a working cell bank.
- The process is intended to enable the production of millions of doses at scale.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 10, 2025
- Reporting period: Quarter and Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Lineage Cell Therapeutics successfully completed the second tranche of a registered direct offering to Broadwood Partners, L.P., following shareholder approval required for NYSE compliance. The company raised $6 million in this tranche and previously raised $24 million in November 2024.
🚩 Red Flags
- Related-party transaction: Broadwood Partners, L.P. is an affiliate of Neal Bradsher, a member of the company's Board of Directors.
- Dilutive financing: Issuance of common shares and warrants at $0.76 per unit to raise capital for working capital/R&D.
- Warrant trigger event: Warrants expire 90 days after public disclosure of intent to advance OpRegen® into a multi-center phase 2 or 3 clinical trial, creating potential volatility around clinical news.
📋 Key Facts
- Closed second tranche of a registered direct offering on January 27, 2025.
- Issued 7,894,737 common shares and warrants to Broadwood Partners, L.P. at $0.76 per unit (combined price).
- Received $6 million in gross proceeds from this closing; previously received $24 million in November 2024.
- Warrants issued to Broadwood have an exercise price of $0.91, exercisable starting May 21, 2025.
- Potential for up to $36 million in additional gross proceeds upon full warrant exercise.
- Shareholders approved the issuance to comply with NYSE American LLC listing standards.
Lineage Cell Therapeutics announced a registered direct offering of up to 39,473,688 common shares and warrants at $0.76 per unit. The offering includes a significant investment from Broadwood Partners, an affiliate of a board member, which requires shareholder approval.
🚩 Red Flags
- Related-party transaction: Broadwood Partners is an affiliate of Neal Bradsher, a board member.
- Significant dilution: The offering involves nearly 40 million shares at a low price point ($0.76).
- Contingent warrant expiration: Warrants expire upon specific clinical milestones (Roche/Genentech phase 2/3 trial advancement), creating complex cap table dynamics.
📋 Key Facts
- Aggregate offering size: Up to 39,473,688 common shares and accompanying warrants.
- Pricing: $0.76 per common share and one warrant per share.
- Gross proceeds: ~$24 million from unaffiliated institutional investors; ~$6 million from Broadwood Partners.
- Potential additional proceeds: Up to $36 million via future exercise of warrants.
- Warrant terms: Exercise price of $0.91; includes a milestone-based expiration linked to Roche/Genentech clinical trial advancement (OpRegen®).
- Broadwood investment requires shareholder approval due to NYSE American listing requirements regarding affiliate transactions.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2024. The filing serves as a formal notice that a press release containing these results was issued on November 14, 2024.
📋 Key Facts
- Company announced quarterly financial results for the period ending September 30, 2024.
- The announcement was made via press release dated November 14, 2024.
- Financial results are furnished in Exhibit 99.1 and are not being filed under Section 18 of the Exchange Act.
Lineage Cell Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice of the release of quarterly earnings via press release.
📋 Key Facts
- The company issued a press release on August 8, 2024, regarding financial results.
- The reporting period covered is the quarter ended June 30, 2024.
- The filing includes Exhibit 99.1 containing the full press release.
Lineage Cell Therapeutics, Inc. announced the dismissal of its independent registered public accounting firm, WithumSmith+Brown, PC, and the simultaneous engagement of Moss Adams LLP, effective June 11, 2024.
🚩 Red Flags
- Auditor change (dismissal of previous firm) is a common red flag in micro-cap biotech companies, though the company explicitly states no disagreements occurred.
📋 Key Facts
- Dismissal of WithumSmith+Brown, PC (Withum) approved by the Audit Committee on June 11, 2024.
- Engagement of Moss Adams LLP as the new independent auditor for the fiscal year ending December 31, 2024.
- Withum audited consolidated financial statements for years ended Dec 31, 2023, and Dec 31, 2022.
- The company stated there were no disagreements with Withum regarding accounting principles, practices, or auditing scope/procedures during the relevant periods.
- No reportable events occurred as defined by Item 304(a)(1)(v) of Regulation S-K.
Lineage Cell Therapeutics, Inc. filed an 8-K reporting the results of its annual meeting of shareholders held on June 11, 2024. The filing includes amendments to the company's bylaws and the ratification of the independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on June 11, 2024.
- Nine directors were elected to hold office until the 2025 annual meeting: Michael H. Mulroy, Dipti Amin, Deborah Andrews, Don M. Bailey, Neal C. Bradsher, Brian M. Culley, Anula Jayasuriya, Angus C. Russell, and an unnamed ninth nominee (implied by list).
- Shareholders ratified the appointment of WithumSmith+Brown, PC as independent registered public accounting firm for FY2024.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The Board amended and restated the Company's bylaws to conform with California Corporations Code regarding electronic meetings, emergency meetings, and shareholder nomination procedures.
Lineage Cell Therapeutics, Inc. has filed a prospectus supplement to its shelf registration statement (Form S-3) to facilitate the sale of common shares via an At-The-Market (ATM) offering. The aggregate offering price for these ATM shares is up to $39,966,424.
🚩 Red Flags
- Potential dilution of existing shareholders through the issuance of new common shares.
- Continuous capital raising via ATM programs is often indicative of high cash burn typical in biotech/clinical-stage companies.
📋 Key Facts
- Company filed a prospectus supplement on May 14, 2024.
- The offering relates to an existing shelf registration statement (Form S-3) declared effective on May 14, 2024.
- Aggregate offering price of up to $39,966,424 in common shares.
- B. Riley Securities, Inc. is acting as the sales agent for the ATM program.
- The sale will be conducted from time to time through an At-The-Market (ATM) mechanism.
Lineage Cell Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 9, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing is a standard announcement of quarterly financial results via press release (Exhibit 99.1).
Lineage Cell Therapeutics entered into a new at-the-market (ATM) sales agreement with B. Riley Securities to sell common shares and terminated its previous ATM program with Cantor Fitzgerald. Additionally, the company reported an FDA delay in reviewing its IND for the OPC1 clinical study due to agency workload.
🚩 Red Flags
- Potential dilution through new ATM offering with B. Riley Securities.
- Regulatory delay: FDA review of IND for OPC1 is ongoing and delayed due to agency workload.
- Switching sales agents (Cantor Fitzgerald to B. Riley) often indicates a need for immediate liquidity or restructuring of financing terms.
📋 Key Facts
- Entered into a Sales Agreement with B. Riley Securities on March 22, 2024, for 'at-the-market' (ATM) offerings of common shares.
- B. Riley will receive a commission of up to 3.0% on gross proceeds from sales.
- Terminated the prior Sales Agreement with Cantor Fitzgerald & Co. effective March 18, 2024; approximately $6.66 million had been sold under that program previously.
- FDA advised Lineage not to initiate the proposed DOSED clinical study for OPC1 until receiving feedback, which is anticipated by April 26, 2024.
- The company successfully resolved an initial clinical information request from the FDA on March 18, 2024.
Lineage Cell Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Quarter and Year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Lineage Cell Therapeutics, Inc. announced the scheduling of its 2024 Annual Meeting of Shareholders for June 11, 2024. The filing outlines specific deadlines for shareholder nominations and proposals in accordance with company bylaws.
📋 Key Facts
- The 2024 Annual Meeting is scheduled for June 11, 2024.
- Shareholder notice of intention to nominate directors must be received by March 15, 2024.
- Shareholder proposals under Rule 14a-8 must be received by March 29, 2024.
- The meeting date is more than 30 days before the one-year anniversary of the 2023 annual meeting.
Lineage Cell Therapeutics, Inc. entered into a stock purchase agreement for a registered direct offering of 13,461,540 common shares at $1.04 per share. The company expects to raise approximately $14.0 million in gross proceeds to fund clinical trials, R&D, and working capital.
🚩 Red Flags
- Significant dilution: The offering of over 13 million shares at $1.04 represents a substantial increase in share count.
- Related-party involvement: Broadwood Partners, L.P. (affiliated with board member Neal Bradsher) and Don M. Bailey (board member) are participating in the offering.
📋 Key Facts
- Total shares offered: 13,461,540 common shares
- Offering price: $1.04 per share
- Expected aggregate gross proceeds: $14.0 million (before expenses)
- Closing date expected on or about February 8, 2024
- Proceeds intended for clinical trials, R&D, G&A, and working capital needs